» Articles » PMID: 35008320

Outcomes After Surgical Treatment of Metastatic Disease in the Adrenal Gland; Valuable for the Patient?

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2022 Jan 11
PMID 35008320
Authors
Affiliations
Soon will be listed here.
Abstract

The adrenal glands are common dissemination sites for metastasis of various solid tumors. Surgical treatment is often recommended because targeted therapies and immunotherapy are frequently ineffective for adrenal metastasis. We report the experience with short-term and long-term surgical outcomes of patients undergoing surgery for adrenal metastasis in two hospitals. A retrospective, multicenter study was performed to analyze patient characteristics, tumor-related data, perioperative outcomes, and oncological outcomes. Postoperative complications that occurred within 30 days were scored according to the Clavien Dindo classification. Metastatic adrenalectomy was performed in 95 patients. We observed an increase from an average of 3 metastatic adrenalectomies per year between 2001-2005 to 10 between 2015-2019. The most frequent underlying malignancies were colorectal and lung cancer. In 55.8%, minimal invasive adrenalectomy was performed, including six conversions to open surgery. A total of 37.9% of patients had postoperative complications, of which ileus or gastroparesis, wound problems, pneumonia, and heart arrhythmias were the most occurring complications. Improved cancer care has led to an increased demand for metastatic adrenalectomy over the past years. Complication rates of 37.9% are significant and cannot be neglected. Therefore, multidisciplinary teams should weigh the decision to perform metastatic adrenalectomy for each patient individually, taking into account the drawbacks of the described morbidity versus the potential benefits.

Citing Articles

Serum hemoglobin and albumin levels serve as prognostic predictors after adrenal metastasectomy.

Ma N, He X, Nei Q, Liu Z, Chen X, Chang H Discov Oncol. 2024; 15(1):759.

PMID: 39692934 PMC: 11655711. DOI: 10.1007/s12672-024-01647-0.


Retrospective Analysis of Efficacy and Toxicity of Stereotactic Body Radiotherapy and Surgical Resection of Adrenal Metastases from Solid Tumors.

Lutscher J, Gelpke H, Zehnder A, Mauti L, Padevit C, John H Cancers (Basel). 2024; 16(15).

PMID: 39123383 PMC: 11311624. DOI: 10.3390/cancers16152655.


Surgery for advanced adrenal malignant disease: recommendations based on European Society of Endocrine Surgeons consensus meeting.

Mihai R, De Crea C, Guerin C, Torresan F, Agcaoglu O, Simescu R Br J Surg. 2024; 111(1).

PMID: 38265812 PMC: 10805373. DOI: 10.1093/bjs/znad266.


Risk factors of local control in adrenal metastases treated by stereotactic body radiation therapy - a systematic review and meta-analysis.

Liao X, Kishi K, Du K, Komaki R, Mizoe J, Aikawa G Front Oncol. 2023; 13:1193574.

PMID: 38045003 PMC: 10691549. DOI: 10.3389/fonc.2023.1193574.


Adrenal Metastasectomy in the Era of Immuno- and Targeted Therapy.

Wachtel H, Dickson P, Fisher S, Kiernan C, Solorzano C Ann Surg Oncol. 2023; 30(7):4146-4155.

PMID: 37079202 DOI: 10.1245/s10434-023-13474-8.

References
1.
Schreuders E, Ruco A, Rabeneck L, Schoen R, Sung J, Young G . Colorectal cancer screening: a global overview of existing programmes. Gut. 2015; 64(10):1637-49. DOI: 10.1136/gutjnl-2014-309086. View

2.
Pfannschmidt J, Schlolaut B, Muley T, Hoffmann H, Dienemann H . Adrenalectomy for solitary adrenal metastases from non-small cell lung cancer. Lung Cancer. 2005; 49(2):203-7. DOI: 10.1016/j.lungcan.2005.02.012. View

3.
Ramsingh J, ODwyer P, Watson C . Survival outcomes following adrenalectomy for isolated metastases to the adrenal gland. Eur J Surg Oncol. 2019; 45(4):631-634. DOI: 10.1016/j.ejso.2019.01.006. View

4.
Mitchell I, Nwariaku F . Adrenal masses in the cancer patient: surveillance or excision. Oncologist. 2007; 12(2):168-74. DOI: 10.1634/theoncologist.12-2-168. View

5.
Spartalis E, Drikos I, Ioannidis A, Chrysikos D, Athanasiadis D, Spartalis M . Metastatic Carcinomas of the Adrenal Glands: From Diagnosis to Treatment. Anticancer Res. 2019; 39(6):2699-2710. DOI: 10.21873/anticanres.13395. View